These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 9723245)

  • 1. Low exposure to cyclosporine is a risk factor for the occurrence of chronic rejection after kidney transplantation.
    Citterio F; Torricelli P; Serino F; Foco M; Pozzetto U; Fioravanti P; Castagneto M
    Transplant Proc; 1998 Aug; 30(5):1688-90. PubMed ID: 9723245
    [No Abstract]   [Full Text] [Related]  

  • 2. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 3. Variability of Sandimmune pharmacokinetics in renal transplant patients.
    Wingerchuk C; Heim-Duthoy KL; Macres MG; Kasiske BL
    Transplant Proc; 1998 Aug; 30(5):1656-7. PubMed ID: 9723230
    [No Abstract]   [Full Text] [Related]  

  • 4. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 5. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
    Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
    Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimization of cyclosporine therapy in kidney transplantation.
    Remuzzi G; Perico N; Gaspari F
    Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238
    [No Abstract]   [Full Text] [Related]  

  • 7. Greater variability of dose-corrected cyclosporine C2 concentrations in renal recipients with acute rejection.
    Chueh SC; Liao CH; Lai MK
    Transplant Proc; 2003 Feb; 35(1):234-5. PubMed ID: 12591378
    [No Abstract]   [Full Text] [Related]  

  • 8. C2 single-point sampling to evaluate cyclosporine exposure in long-term renal transplant recipients.
    Citterio F; Scatà MC; Borzi MT; Pozzetto U; Castagneto M
    Transplant Proc; 2001; 33(7-8):3133-6. PubMed ID: 11750347
    [No Abstract]   [Full Text] [Related]  

  • 9. A critical appraisal of cyclosporine A pharmacokinetics in pediatric kidney transplantation using a microemulsion galenic formulation (Neoral).
    Foradori A; Pinto VM; Elberg A
    Transplant Proc; 1998 Aug; 30(5):1666-7. PubMed ID: 9723235
    [No Abstract]   [Full Text] [Related]  

  • 10. A two-year study of the new cyclosporine formulation Consupren in de novo renal transplant patients.
    Stephan AG; Barbari A; Masri M; Kamel G; Barakat Khoury W; Karam A; Mokhbat J; Kilany H
    Transplant Proc; 1998 Nov; 30(7):3563-4. PubMed ID: 9838560
    [No Abstract]   [Full Text] [Related]  

  • 11. Early achievement of target cyclosporine levels during initial post-transplant period with a novel dosing strategy.
    Chueh SC; Lai MK
    Transplant Proc; 1998 Aug; 30(5):1681-2. PubMed ID: 9723242
    [No Abstract]   [Full Text] [Related]  

  • 12. Role of postdose cyclosporine monitoring in living renal transplant recipients.
    Thomas R; Minz M; Singh B; Heer M; Kashyap R
    Transplant Proc; 2004 Sep; 36(7):2104. PubMed ID: 15518761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of variability of cyclosporine pharmacokinetics on long-term renal allograft survival.
    Markell MS; Homel P; Sumrani N; Hong JH; Distant DA; Miles AM; Sommer BG; Friedman EA
    Transplant Proc; 1998 Aug; 30(5):1980-2. PubMed ID: 9723360
    [No Abstract]   [Full Text] [Related]  

  • 14. Conversion from Sandimmune to Neoral in renal transplant: functional histopathological, and pharmacokinetic changes.
    Roessler E; Herrera S; Espinoza M; Ayala A; Reynolds E; González F; Espinoza O; Undurraga A; Muñoz R; Arcos O; Galaz G
    Transplant Proc; 1998 Aug; 30(5):1756-7. PubMed ID: 9723268
    [No Abstract]   [Full Text] [Related]  

  • 15. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 16. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
    Crocker J; Renton K; Wade A; McLellan H; Acott P
    Transplant Proc; 1998 Aug; 30(5):2002-5. PubMed ID: 9723369
    [No Abstract]   [Full Text] [Related]  

  • 17. Preservation of renal function during maintenance therapy with cyclosporine.
    Serón D; Moreso F
    Transplant Proc; 2004 Mar; 36(2 Suppl):257S-260S. PubMed ID: 15041349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conversion of C-0 to C-2 monitoring of cyclosporine in stable kidney transplant patients.
    Jirasiritham S; Mavichak V; Danviriyasup K; Jirasiritham S
    Transplant Proc; 2003 Feb; 35(1):236-7. PubMed ID: 12591379
    [No Abstract]   [Full Text] [Related]  

  • 19. Convenience of level of cyclosporine-Neoral at time 3 to determine the area under curve in renal transplant.
    Rial MC; Frias S; Argento J; Tessler J; Casadei D
    Transplant Proc; 1997; 29(1-2):292-3. PubMed ID: 9123001
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of calcium channel blockers in renal allograft patients receiving cyclosporine.
    Suh BY; Kwun OS; Kwun KB
    Transplant Proc; 1998 Nov; 30(7):3558-60. PubMed ID: 9838558
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.